Can analysts adopt a bullish outlook for Akebia Therapeutics, Inc. (NASDAQ:AKBA)?

January 10, 2018 - By Richard Conner

 Can analysts adopt a bullish outlook for Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
Investors sentiment decreased to 2.23 in Q3 2017. Its down 0.02, from 2.25 in 2017Q2. It dropped, as 17 investors sold Akebia Therapeutics, Inc. shares while 14 reduced holdings. 25 funds opened positions while 44 raised stakes. 28.78 million shares or 10.48% more from 26.05 million shares in 2017Q2 were reported.
The Massachusetts-based Fmr Lc has invested 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Mufg Americas Corp invested in 0% or 328 shares. Bnp Paribas Arbitrage holds 4,329 shares or 0% of its portfolio. Alyeska Inv Grp Inc L P holds 0.02% or 127,274 shares in its portfolio. Eam Lc, California-based fund reported 235,470 shares. Nantahala Capital Mngmt Lc stated it has 1.32% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Caprock Grp Inc reported 14,450 shares or 0.06% of all its holdings. Parametric Port Assocs holds 0% or 105,198 shares. Dafna Cap Management Limited Liability Co invested in 135,738 shares. Metropolitan Life Insur New York accumulated 29,941 shares. Legal General Group Public Ltd Com invested in 11,519 shares. Raymond James And, a Florida-based fund reported 36,838 shares. Goldman Sachs Group has invested 0% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). California Public Employees Retirement Systems invested in 59,000 shares. Adams Diversified Equity Fund holds 0.05% or 47,300 shares.

Since August 15, 2017, it had 0 insider purchases, and 5 sales for $377,477 activity. Hadas Nicole R. sold 7,803 shares worth $155,188. Nash Duane sold 1,188 shares worth $23,332.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Coverage

Among 11 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Akebia Therapeutics Inc had 24 analyst reports since August 13, 2015 according to SRatingsIntel. The company was maintained on Thursday, November 2 by RBC Capital Markets. The rating was maintained by H.C. Wainwright on Tuesday, December 27 with “Buy”. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. H.C. Wainwright initiated Akebia Therapeutics, Inc. (NASDAQ:AKBA) on Monday, December 7 with “Buy” rating. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) earned “Neutral” rating by Credit Suisse on Thursday, January 21. The rating was maintained by JMP Securities on Wednesday, December 21 with “Mkt Outperform”. Aegis Capital maintained the stock with “Buy” rating in Friday, June 30 report. Brean Capital initiated the stock with “Buy” rating in Thursday, September 29 report. The firm earned “Buy” rating on Wednesday, October 4 by Mizuho. The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) earned “Equal Weight” rating by Morgan Stanley on Thursday, August 13. Below is a list of Akebia Therapeutics, Inc. (NASDAQ:AKBA) latest ratings and price target changes.

18/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Initiate
07/12/2017 Broker: BTIG Research Rating: Buy New Target: $30.0 Initiate
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $17.0 Maintain
04/10/2017 Broker: Mizuho Rating: Buy New Target: $24.0 Initiate
15/09/2017 Broker: RBC Capital Markets Rating: Sector Perform New Target: $17 Initiates Coverage On
09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $24.0000 Maintain

The stock increased 3.11% or $0.47 during the last trading session, reaching $15.57. About 281,035 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has risen 76.80% since January 10, 2017 and is uptrending. It has outperformed by 60.10% the S&P500.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology. The company has market cap of $735.98 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. It currently has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

More notable recent Akebia Therapeutics, Inc. (NASDAQ:AKBA) news were published by: Seekingalpha.com which released: “Akebia Therapeutics Forges Deals To Manage Costs And Profitability” on June 05, 2017, also Businesswire.com with their article: “Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of …” published on January 04, 2018, Fool.com published: “Why Akebia Therapeutics Inc. Tanked Today” on March 07, 2017. More interesting news about Akebia Therapeutics, Inc. (NASDAQ:AKBA) were released by: Seekingalpha.com and their article: “Revisiting Akebia Therapeutics” published on July 05, 2017 as well as Businesswire.com‘s news article titled: “Akebia Therapeutics to Participate in Upcoming Investor Conferences” with publication date: November 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.